Research presented Nov. 2 at the Transcatheter Cardiovascular Therapeutics scientific symposium in Denver demonstrates patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) derive better clinical outcomes with PCI at similar cost to medical therapy alone.

An image-guided cardiac device designed to repair the mitral valve while a patient’s heart is still beating could provide a safe, effective alternative to traditional open heart surgery, according to research presented Nov. 1 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Denver.

Differences in exercise duration for patients with stable angina who received either PCI or a placebo treatment were not statistically significant, according to research presented Nov. 2 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and published simultaneously in The Lancet.

Interventional cardiologists are exposed to chronic low-dose radiation, which can lead to adverse health conditions. At a Nov. 1 presentation at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Denver, Wieneke Vlastra, MD, reported a 20 percent decrease in radiation exposure for operators when a lead-free disposable pad was placed on the patient.

Transcatheter mitral valve replacement (TMVR) using a new self-expanding, tri-leaflet bovine valve was a success in the majority of patients enrolled in a pioneering global study, according to data presented this week at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in Denver.

The first three-year results of Abbott’s ABSORB III trial were announced at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 31, nearly two months after Abbott Vascular withdrew its bioresorbable scaffold from the commercial market.

Though provisional stenting (PS) is the most popular PCI technique used to treat distal left main (LM) bifurcation lesions, a double kissing (DK) crush two-stent technique yielded more positive results in a large-scale randomized trial comparing the two, according to research presented at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

Heart patients with left main coronary artery disease (LMCAD) could benefit from more immediate results when receiving percutaneous coronary intervention (PCI) over coronary artery bypass graft surgery (CABG), according to research presented at this year’s Transcatheter Cardiovascular Therapeutics (TCT) symposium, though both procedures yield similar quality of life improvements after three years.